Company profile for Epsilogen

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life. The epsilon constant region of IgE binds very tightly to its cognate receptor (FcεRI) on the surface of immune effector cells including macrophages, monocytes, basop...
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life. The epsilon constant region of IgE binds very tightly to its cognate receptor (FcεRI) on the surface of immune effector cells including macrophages, monocytes, basophils and eosinophils. This interaction is up to 10,000 fold greater than the gamma chain of IgG has for its equivalent receptor.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
London BioScience Innovation Centre, 2 Royal College Street, London NW1 0NH
Telephone
Telephone
+44 (0) 203 657 7612
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-10-07/epsilogen-announces-the-appointment-of-cristina-oliva-md-phd-as-chief-medical-officer

PHARMIWEB
07 Oct 2025

https://www.fiercebiotech.com/biotech/uks-epsilogen-acquires-fellow-immunoglobin-biotech-tigatx-expand-cancer-antibody-options

FIERCE BIOTECH
08 Apr 2025

https://www.businesswire.com/news/home/20250406268542/en/Epsilogen-Announces-Acquisition-of-TigaTx-Inc.-to-Create-Worlds-Leading-Pan-Isotype-Cancer-Antibody-Company

BUSINESSWIRE
07 Apr 2025

https://www.businesswire.com/news/home/20241202478799/en

BUSINESSWIRE
02 Dec 2024

https://www.businesswire.com/news/home/20240908069943/en

BUSINESSWIRE
09 Sep 2024

https://www.businesswire.com/news/home/20240707808760/en

BUSINESSWIRE
08 Jul 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty